Previous Close | 97.00 |
Open | 94.74 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 94.74 - 94.74 |
52 Week Range | 90.12 - 109.00 |
Volume | |
Avg. Volume | 44,098 |
Market Cap | 197.27B |
Beta (5Y Monthly) | 0.47 |
PE Ratio (TTM) | 21.53 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.76 (3.97%) |
Ex-Dividend Date | Mar 07, 2024 |
1y Target Est | N/A |
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday. Mariana Oncology is working on novel radioligand cancer therapies (RLTs) that have not yet been tested on humans. "The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities," Novartis said in a statement.